SAN MARINO, Calif., March 25 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.
Rexin-G demonstrates profound single agent efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, uterine cancer, gastric cancer, malignant melanoma, validating Epeius Biotechnologies' in vivo targeted gene delivery platform [Int'l J Oncol, 2006, 2007].
The response rates seen with Rexin-G are unmatched by any other tumor-
targeted gene delivery system. The U.S. FDA has granted Orphan Drug Status
to Rexin-G based on its performance as a single therapeutic agent in
treating chemotherapy refractory pancreatic cancer. Based on its exemplary
record of safety and efficacy as an anti-cancer agent in a broad spectrum
of chemo- resistant tumors, Rexin-G received accelerated approval for the
treatment of all solid tumors by the Philippine BFAD, leading to its
registration. Currently, Rexin-G is being tested as a single therapeutic
agent in three separate U.S. Phase I/II Trials for recurrent or metastatic
cancers of the breast or pancreas and for bone and soft tissue sarcoma
respectively. Additionally, a Phase II Registration Protocol is underway
for chemo-resistant osteosarcoma in Los
|SOURCE Epeius Biotechnologies Corporation|
Copyright©2008 PR Newswire.
All rights reserved